Skip to main content
. 2020 Dec 12;11(12):1061. doi: 10.1038/s41419-020-03266-3

Fig. 4. Tazemetostat-induced PUMA via ROS/ER stress axis.

Fig. 4

A HCT116 cells were treated with 0.5 μM tazemetostat for 24 h. Indicated proteins were analyzed by western blotting. B HCT116 cells were treated with 0.5 μM tazemetostat, 1 μM salubrinal or their combination for 24 h. Indicated proteins were analyzed by western blotting. C HCT116 cells were treated with the combination of 2.5 μg/mL 5-FU and 0.5 μM tazemetostat with or without salubrinal for 24 h. Indicated proteins were analyzed by western blotting. D HCT116 cells were treated with 0.5 μM tazemetostat for 12 or 24 h. The expression levels of ROS were measured by DHE staining and analyzed by flow cytometry. E HCT116 cells were treated with 0.5 μM tazemetostat for 24 h. Indicated proteins were analyzed by western blotting. F HCT116 cells were treated with the combination of 2.5 μg/mL 5-FU and 0.5 μM tazemetostat with or without NAC for 24 h. Indicated proteins were analyzed by western blotting. G HCT116 cells were treated with the combination of 2.5 μg/mL 5-FU and 0.5 μM tazemetostat with or without NAC for 24 h. Apoptosis was analyzed by flow cytometry. The results were expressed as the mean ± SD of three independent experiments. **P < 0.01.